Patents by Inventor Gali Shapira

Gali Shapira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10369281
    Abstract: Devices, systems and methods for adjusting fluid delivery based on past or historical fluid delivery data and/or personal parameters of a user are disclosed. Devices, and corresponding systems and methods, may comprise a dispensing unit configured to deliver a fluid from a reservoir into the body of a user and a processor having instructions operating thereon to retrieve data relating to one or more time windows from a memory, assess a correction delivery for the one or more time windows based on the data, determine a new CIR value for the one or more time windows if the correction delivery regularly follows a meal bolus and/or determine a new basal delivery profile for the one or more time windows if the correction delivery regularly precedes a meal bolus.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: August 6, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Iddo Gescheit
  • Patent number: 10350354
    Abstract: A device and a method for prevention of hypoglycemia are disclosed. In one aspect, the device and the method for prevention of hypoglycemia can comprise receiving a target blood glucose (TBG) level corresponding to a desired level of glucose in a patient's body during a fasting time period; receiving a bedtime blood glucose (BBG) level corresponding to a level of glucose in the patient's body substantially at a beginning of the fasting time period (e.g. before bedtime); receiving a first set of parameters corresponding to a medical state of the patient; determining a therapeutic course of action based on the levels of the TBG, BBG and the medical state of the patent; and administering the therapeutic course of action to the patient.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: July 16, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Neesha Ramchandani
  • Patent number: 10272199
    Abstract: Delivery of more than one therapeutic fluid as a means to control symptoms of a health conditions is disclosed. More than one therapeutic fluid may be dispensed from more than one reservoir and delivered to a user's body via one or more cannula that penetrate the skin. The therapeutic fluids may be delivered by action of one or more pumping mechanisms that may be controlled by a processor in a portable, ambulatory device. The therapeutic fluids may optionally be insulin and one or more of an amylin analog, pramlintide acetate and an exenatide, and the health condition may optionally be diabetes. This device can be used in combination with a glucometer.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: April 30, 2019
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira
  • Patent number: 9919105
    Abstract: Devices, systems and methods for determining a recommended bolus dose of therapeutic fluid to be delivered to the body are disclosed. Such a recommended bolus dose may be provided by establishing an initial bolus dose for a user based on one or more first parameters relating to the user and adjusting (e.g., increasing or decreasing) this initial bolus dose amount based on one or more second user parameters by multiplying the initial bolus dose by one or more multiplier values that correlate to at least one of the second parameters and/or by adding or subtracting an absolute value of at least one of the second parameters from the initial bolus dose amount.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: March 20, 2018
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Iddo M. Gescheit
  • Patent number: 9872959
    Abstract: A method and a system for determining insulin sensitivity (IS) is described. In one aspect the method and the system can be implemented by receiving a first parameter corresponding to an insulin dose in a subcutaneous tissue; applying a first kinetic model to obtain a plasma insulin concentration based on the first parameter; receiving a second parameter corresponding to a plasma glucose concentration; determining the insulin sensitivity (IS) based on the plasma insulin concentration and the second parameter.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: January 23, 2018
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Iddo Gescheit
  • Patent number: 9724468
    Abstract: The present disclosure presents systems, devices and methods for administration of a therapeutic fluid to the body of a patient at a transient basal delivery profile, and enabling modification of the transient profile. Some embodiments include a user interface enabling input of one or more transient basal related parameters, and a processor having a basal programming application operating thereon. The basal programming application configured for determining a transient basal profile based on at least one or more transient basal related parameters. The transient basal profile comprises a plurality of phases and wherein each of the plurality of phases is characterized by a duration and at least one basal rate. In some embodiments, at least one of the plurality of phases includes either a basal overshot or a basal undershot. Some embodiments may also include a pump for dispensing the therapeutic fluid from a reservoir to the body of the patient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: August 8, 2017
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira
  • Patent number: 9597451
    Abstract: Embodiments of the present disclosure are directed to systems, devices/apparatuses and methods for assessing a residual insulin value for a user/patient. Such embodiments may be implemented by selecting a first value corresponding to a duration of insulin action; selecting a second value corresponding to a lock out time duration, selecting a first time period beginning at a time point T0 minus the first value and ending at the time point T0 minus the second value, selecting one or more boluses delivered during the first time period; for each of the one or more boluses selecting a corresponding residual insulin value estimated at the time point T0, computing the cumulative residual insulin value by summation of the corresponding residual insulin values.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: March 21, 2017
    Assignee: Roche Diagnostic Operations, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Iddo M. Gescheit
  • Patent number: 9457145
    Abstract: Systems, devices and methods are presented in the subject disclosure for recommending an insulin dose adapted for use with an insulin delivery device. In some embodiments, the method may include receiving blood glucose (BG) data, determining one or more insulin sensitivity (IS) values associated with the BG data, and determining an insulin dose based on the determined one or more IS values. A system for carrying out such a method is also presented.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: October 4, 2016
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Iddo M. Gescheit
  • Patent number: 9387033
    Abstract: Products and methods directed to the improved infusion of fluids are disclosed. Such products and methods can be used to more efficiently and efficaciously administer therapeutic pharmaceuticals to a subject in need of treatment. In many instances, the systems comprise a therapeutic fluid delivery system and a mechanism for enhancing the absorption of the therapeutic fluid. The enhancement of the absorption of the therapeutic fluid is generally performed locally i.e., at or near the site of administration of the therapeutic fluid. The system and methods can be used to deliver any number of therapeutic fluids including but not limited to insulin.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: July 12, 2016
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Illai Gescheit
  • Publication number: 20160106918
    Abstract: A method and a system for determining insulin sensitivity (IS) is described. In one aspect the method and the system can be implemented by receiving a first parameter corresponding to an insulin dose in a subcutaneous tissue; applying a first kinetic model to obtain a plasma insulin concentration based on the first parameter; receiving a second parameter corresponding to a plasma glucose concentration; determining the insulin sensitivity (IS) based on the plasma insulin concentration and the second parameter.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Inventors: Ofer Yodfat, Gali Shapira, Iddo Gescheit
  • Publication number: 20160106917
    Abstract: The present disclosure presents systems, devices and methods for administration of a therapeutic fluid to the body of a patient at a transient basal delivery profile, and enabling modification of the transient profile. Some embodiments include a user interface enabling input of one or more transient basal related parameters, and a processor having a basal programming application operating thereon. The basal programming application configured for determining a transient basal profile based on at least one or more transient basal related parameters. The transient basal profile comprises a plurality of phases and wherein each of the plurality of phases is characterized by a duration and at least one basal rate. In some embodiments, at least one of the plurality of phases includes either a basal overshot or a basal undershot. Some embodiments may also include a pump for dispensing the therapeutic fluid from a reservoir to the body of the patient.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Inventors: Ofer Yodfat, Gali Shapira
  • Patent number: 9248231
    Abstract: The present disclosure presents systems, devices and methods for administration of a therapeutic fluid to the body of a patient at a transient basal delivery profile, and enabling modification of the transient profile. Some embodiments include a user interface enabling input of one or more transient basal related parameters, and a processor having a basal programming application operating thereon. The basal programming application configured for determining a transient basal profile based on at least one or more transient basal related parameters. The transient basal profile comprises a plurality of phases and wherein each of the plurality of phases is characterized by a duration and at least one basal rate. In some embodiments, at least one of the plurality of phases includes either a basal overshot or a basal undershot. Some embodiments may also include a pump for dispensing the therapeutic fluid from a reservoir to the body of the patient.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: February 2, 2016
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira
  • Patent number: 9244077
    Abstract: A method and a system for determining insulin sensitivity (IS) is described. In one aspect the method and the system can be implemented by receiving a first parameter corresponding to an insulin dose in a subcutaneous tissue; applying a first kinetic model to obtain a plasma insulin concentration based on the first parameter; receiving a second parameter corresponding to a plasma glucose concentration; determining the insulin sensitivity (IS) based on the plasma insulin concentration and the second parameter.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: January 26, 2016
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira, Iddo Gescheit
  • Publication number: 20160001002
    Abstract: Delivery of more than one therapeutic fluid as a means to control symptoms of a health conditions is disclosed. More than one therapeutic fluid may be dispensed from more than one reservoir and delivered to a user's body via one or more cannula that penetrate the skin. The therapeutic fluids may be delivered by action of one or more pumping mechanisms that may be controlled by a processor in a portable, ambulatory device. The therapeutic fluids may optionally be insulin and one or more of an amylin analog, pramlintide acetate and an exenatide, and the health condition may optionally be diabetes. This device can be used in combination with a glucometer.
    Type: Application
    Filed: September 18, 2015
    Publication date: January 7, 2016
    Inventors: Ofer Yodfat, Gali Shapira
  • Patent number: 9199031
    Abstract: Devices, apparatuses and methods for controlling blood-glucose levels during exercise are described. For example, an insulin infusion apparatus can include a control module to regulate a rate of therapeutic fluid release into a body of a patient based on a determined therapeutic fluid requirement profile, and a dispensing unit to release therapeutic fluid at the regulated rate. The methods and devices can be implemented by receiving a first value corresponding to a first glucose concentration before an exercise activity of a user; receiving a second value corresponding to a second glucose concentration after the exercise activity for the user; determining a glucose concentration change based on a difference between the second value and the first value; modifying a basal rate based on a comparison of the glucose concentration change with a predetermined threshold value; and, recording the modified basal rate in a computer-readable memory device.
    Type: Grant
    Filed: December 25, 2008
    Date of Patent: December 1, 2015
    Inventors: Ofer Yodfat, Gali Shapira, Illai Gescheit
  • Patent number: 9173991
    Abstract: Delivery of more than one therapeutic fluid as a means to control symptoms of a health conditions is disclosed. More than one therapeutic fluid may be dispensed from more than one reservoir and delivered to a user's body via one or more cannula that penetrate the skin. The therapeutic fluids may be delivered by action of one or more pumping mechanisms that may be controlled by a processor in a portable, ambulatory device. The therapeutic fluids may optionally be insulin and one or more of an amylin analog, pramlintide acetate and an exenatide, and the health condition may optionally be diabetes.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: November 3, 2015
    Assignee: Roche Diabetes Care, Inc.
    Inventors: Ofer Yodfat, Gali Shapira
  • Patent number: 9056161
    Abstract: A system and a method for delivering fluid to and sensing analyte levels in the body of the patient are disclosed. The system includes a dispensing apparatus configured to infuse fluid into the body of the patient and a sensing apparatus configured to be in communication with the dispensing apparatus and further configured to detect a level of analyte concentration in the body of the patient.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: June 16, 2015
    Assignee: Roche Diabetes Care, INc.
    Inventors: Ofer Yodat, Gavriel J. Iddan, Ruthy Kaidar, Gali Shapira
  • Patent number: 9028409
    Abstract: One or more therapeutic fluids, such as for example insulin can be delivered to a body. In addition or alternatively, the concentrations of one or more analytes can be measured in vivo. A feedback process can be used to regulate levels of the one or more analytes based on the measurements via delivery of the one or more therapeutic fluids. Related systems, apparatus, methods, and/or articles are also described.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: May 12, 2015
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ofer Yodfat, Gavriel J. Iddan, Ruthy Kaidar, Gali Shapira
  • Patent number: 8911423
    Abstract: Techniques and devices are described for allowing a diabetes patient to safely disconnect an insulin infusion system device for a time period. In one aspect, the techniques and devices can be implemented by receiving a maximum glucose amount, a minimum glucose amount, and a contemplated disconnection time; receiving a current glucose amount of the user; determining an expected increase in glucose of the user based on the contemplated disconnection time, an insulin sensitivity of the user and a contemplated basal insulin dose; validating the contemplated disconnection time based on at least one of the expected increase in glucose, the maximum glucose amount, and the minimum glucose amount; and, administering a therapeutic action to the user based on the validation of the contemplated disconnection time.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: December 16, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ofer Yodfat, Gali Shapira
  • Patent number: 8845613
    Abstract: Disclosed is a medical device to treat diabetes. The medical device includes a bolus calculator to determine an insulin bolus based on, at least in part, a glycemic index value associated with an intake to be consumed by a user, the bolus calculator further adapted to determine the insulin bolus using one or more inputs selected from the group consisting of a carbohydrate load of the intake, a current glucose level of the user, a residual insulin of the user, a carbohydrate to insulin ration, an insulin sensitivity of the user and a target glucose level of the user. The bolus calculator is housed in one or more of, for example, an insulin dispensing pump, a handheld remote control unit for the insulin dispensing pump and/or a handheld glucose monitor.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: September 30, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ofer Yodfat, Gali Shapira